Learning points for clinicians
• Hepatic autoimmune overlap syndromes should be considered in patients with evidence of more than one autoimmune hepatic disease.
• Disease resistant to standard immunosuppression and treatment of cholestasis can progress rapidly to cirrhosis and associated complications.
• Specialist input and treatment with novel therapies, such as B-cell depleting agents, present an opportunity to achieve disease remission in refractory cases.
Background
Hepatic overlap syndromes often present with features of autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). Treatment with antiproliferative agents or steroids can prevent disease progression, but immunosuppression is generally less successful in the presence of marked cholestasis. Rituximab has been used to deplete B cells in a small number of patients with AIH. 1 However, the effects of rituximab in refractory hepatic overlap syndrome remain unknown, both clinically and immunologically.
Case presentation
Two sisters with biochemical and histological evidence of AIH/ PBC overlap syndrome were recruited from the hepatology clinic at the University Hospital of Wales (Table 1 ). Patient 1 failed to achieve biochemical remission on azathioprine, prednisolone and ursodeoxycholic acid (UDCA). Patient 2 did not tolerate azathioprine, prednisolone or UDCA, and was treated instead with budesonide and mycophenolate mofetil, which failed to prevent further clinical deterioration. A second liver biopsy demonstrated overlap with progressive fibrosis to early cirrhosis in Patient 2. Rituximab salvage therapy was commenced in both patients, alongside ongoing immunosuppression. Each patient received a 1 g infusion of rituximab at weeks 0 and 2. Patient 1 also received a 1 g infusion of rituximab at weeks 52 and 54. Hepatic fine needle aspiration (FNA) was performed using a 22G spinal needle as described previously. 2 Peripheral blood and FNA cells were collected prior to rituximab infusion at weeks 0 and 2. Patient 1 underwent further sampling at weeks 26, 52 and 54.
Clinical improvement was apparent in both patients, who reported less fatigue. Serum concentrations of alanine transaminase (ALT), alkaline phosphatase (ALP) and immunoglobulins (IgG and IgM) also fell progressively after treatment ( Figure 1A and B ). Lymphocyte subsets were monitored in parallel using polychromatic flow cytometry. As expected, rituximab therapy induced a rapid loss of peripheral and intrahepatic B cells, defined by surface expression of CD19. In Patient 1, peripheral and intrahepatic B cells emerged again at weeks 26 and 52, but waned to undetectable levels after further doses of rituximab at weeks 52 and 54 ( Figure 1C ). Intrahepatic NK cells were also depleted in Patient 1 (Figure 1D and E). There were no substantial changes in the phenotypic attributes (data not shown) or relative frequencies of CD4 þ or CD8 þ T cells after rituximab therapy ( Figure 1F and G). Reference values are shown in parentheses for ALP, ALT, IgG and IgM. Titers are shown in parentheses for autoantibodies.
HLA, human leukocyte antigen; ANA, antineutrophil antibody; SMA, smooth muscle antibody; AMA, antimitochondrial antibody; IAIHG, International Autoimmune Hepatitis Group. 
